Novolog (NVLG) AI Stock Analysis

• Market Cap: 717.22M
• Dividend Yield: 5.58%
• Average Volume (3M): 362.18K
• Price to Earnings (P/E): 25.1
• Beta (1Y): 0.80
• Revenue Growth: 25.30%
• EPS Growth: N/A
• Country: IL
• Employees: 936
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): 0.20
• Shares Outstanding: 510,842,470
• 10 Day Avg. Volume: 600,315
• 30 Day Avg. Volume: 362,175
• PEG Ratio: -0.90
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -206.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: 162.00 ▲(17.90%Upside)

Novolog's strong financial performance is the most significant factor, driven by consistent revenue growth and improved profitability. While the technical analysis shows a mixed picture with potential bearish momentum, the high dividend yield provides a counterbalance in valuation. The overall score reflects a stable financial base with some technical and valuation concerns.

Novolog Business Overview & Revenue Model

Company Description

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.

How the Company Makes Money

Novolog generates revenue primarily through the sale of its insulin products and diabetes-related medications. The company's revenue model is based on direct sales to healthcare providers, hospitals, and pharmacies, both domestically and internationally. Novolog also engages in partnerships with healthcare organizations and governments for large-scale distribution agreements. Additionally, the company invests in research and development to continually improve its products, which helps maintain its competitive edge and supports its pricing strategy. Strategic collaborations with other pharmaceutical companies and participation in clinical trials further contribute to its revenue streams.

Novolog Financial Statement Overview

Summary

Novolog demonstrates strong financial health with consistent revenue growth, improved profitability, and solid cash flow generation. The company has shown a turnaround in profitability with a positive net profit margin and improved return on equity. Operational efficiency is also on the rise, and cash flows remain robust, indicating financial stability.

Income Statement

Novolog's revenue has shown consistent growth over the years, with a noticeable increase from $1.64 billion to $2.02 billion annually. The company has improved its net profit margin from a negative 2.56% to a positive 1.96%, indicating a turnaround in profitability. Gross profit margin remains stable around 8-9%, while EBIT and EBITDA margins have also improved, reflecting better operational efficiency.

Balance Sheet

The debt-to-equity ratio is moderate at 0.54, suggesting a balanced leverage strategy. Stockholders' equity has decreased slightly, but the equity ratio remains healthy at 12.13%, indicating a strong capital base. Return on Equity has improved significantly, moving from negative to positive, showcasing effective management of equity.

Cash Flow

Operating cash flow is robust, supporting a positive free cash flow trajectory. Free cash flow has decreased slightly compared to the previous year, but the company maintains a strong free cash flow to net income ratio, suggesting effective cash conversion. The cash flow from operations remains strong, underscoring financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.09B	2.02B	1.64B	1.51B	1.26B	1.13B
Gross Profit	164.09M	180.78M	173.76M	176.15M	148.96M	129.29M
EBITDA	117.18M	149.39M	130.14M	138.53M	115.92M	104.05M
Net Income	27.37M	39.54M	-42.00M	47.51M	42.32M	40.07M
Balance Sheet
Total Assets	3.12B	3.04B	2.79B	2.43B	2.29B	2.19B
Cash, Cash Equivalents and Short-Term Investments	111.22M	247.60M	232.94M	172.81M	238.71M	176.44M
Total Debt	191.08M	198.47M	215.18M	212.77M	166.81M	154.24M
Total Liabilities	2.73B	2.65B	2.39B	1.97B	1.86B	1.89B
Stockholders Equity	370.37M	368.38M	371.08M	436.00M	424.37M	294.69M
Cash Flow
Free Cash Flow	-3.47M	99.78M	129.06M	63.16M	52.75M	32.87M
Operating Cash Flow	62.91M	158.52M	200.01M	132.65M	83.39M	58.48M
Investing Cash Flow	-58.84M	-50.55M	-72.60M	-124.95M	-69.07M	-28.61M
Financing Cash Flow	-94.14M	-94.59M	-67.71M	-72.96M	47.49M	-39.85M

Novolog Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 137.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Negative. The current price of 137.4 is below the 20-day moving average (MA) of 140.45, below the 50-day MA of 144.68, and below the 200-day MA of 159.70, indicating a bearish trend. The MACD of -0.92 indicates Negative momentum. The RSI at 47.57 is Neutral, neither overbought nor oversold. The STOCH value of 40.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NVLG.

Novolog Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVLG	73 Outperform	717.22M	25.12		5.58%	25.30%	―
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
BRSYF		$255.17M	61.59	7.41%	―	―	―
ILX		700.93M	20.51		1.95%	―	―
DANE	61 Neutral	2.90B	114.96		4.18%	9.32%	―
REKA		146.11M	54.93		―	―	―
SOFW	65 Neutral	752.68M	―		―	17.69%	14.51%

Novolog Corporate Events

Novolog Updates Securities Registry Amid Strategic Option Exercises

Novolog has announced a change in its securities registry due to the exercise of employee options and the allocation of options to the Chairman of the Board. These changes include an increase in the number of securities and a private allocation to Altshuler Shaham Benefits Ltd., reflecting a strategic move to manage corporate shares and options effectively, potentially impacting shareholder value and market perception.

Novolog Announces Major Change in Securities Holdings

Novolog has reported a significant change in the holdings of securities, with Arie Schor, an interested party, increasing his holdings through a private placement. The change involved a single transaction resulting in an acquisition of 2,317,915 securities, now accounting for 100% of the current type of securities held. This adjustment reflects strategic positioning and could impact Novolog’s market dynamics by potentially influencing voting power and capital structure.

Novolog Announces Dividend Distribution for Shareholders

Novolog has announced a dividend distribution for its shareholders, with a record date of February 16, 2025. The company will distribute dividends at a rate of 0.44% to shareholders, which will be paid in cash, reflecting its adherence to its profit distribution policy.

Novolog Approves New Terms for Chairman’s Employment

Novolog held a special meeting to approve the terms of service and employment for the company’s Chairman of the Board, Mr. Arik Shor. The meeting, which required a regular majority for approval, concluded with the decision to approve the terms as outlined. This decision reflects an important operational update for Novolog, potentially affecting its governance structure and ensuring clarity in leadership roles.